http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112867737-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b961bf910c97abac36c6c173abc6f080
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
filingDate 2019-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7efaee44753779fced77867c3b7e8333
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fae781d7d109346bb50fab5dd2b9c9ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_423e9741c6bc7c31c3b990746cedb9c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c339fb0b2495f7a2e1d74fedb566c30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1aaf9e971d45c053744faa16dbbd95d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bdfe513683adf6560e2ad470fd7f60fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7dc5071ffd6aa84a87ff828dac40b1c6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98332e31a8533c49037fb8cb29b9b600
publicationDate 2021-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-112867737-A
titleOfInvention Anti-CD137 antibody and its application
abstract An antibody or antigen-binding fragment thereof that can specifically bind to CD137 is provided, and the light chain variable region and the heavy chain variable region thereof include one or more mutations, and the antibody or antigen-binding fragment thereof is also provided in the preparation of medicaments. the use of.
priorityDate 2018-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018098370-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419586423
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID21942
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100151629
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID10029
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18831
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3604
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID10029

Total number of triples: 38.